Scancell, Cancer Research U.K. deal

Scancell received a worldwide license from Cancer Research Technology Ltd., the commercialization and development arm of Cancer Research U.K., to use 105AD7 to develop new ImmunoBody vaccines for all immunotherapy indications. The human mAb mimics the complement regulatory protein CD55. Cancer Research Technology will receive an upfront payment and is eligible for milestones, plus royalties. Scancell will fund the development of the vaccines. Further financial details were not disclosed. ...